About Ecto-ADP-ribosyltransferase 3
Ecto-ADP-ribosyltransferase 3 (ART3) is a protein
from Homo sapiens identified by UniProt accession
Q13508, 389 residues long.
MolForge cross-references it against 0 known binders and
59 disease associations.
Target properties
| Protein name | Ecto-ADP-ribosyltransferase 3 |
| UniProt accession | Q13508 |
| Gene | ART3 |
| Organism | Homo sapiens |
| Length | 389 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (59)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.30
- protein measurement · score 0.25
- body mass index · score 0.25
- mean corpuscular hemoglobin concentration · score 0.22
- mean corpuscular hemoglobin · score 0.20
- CXCL11 measurement · score 0.19
- C-X-C motif chemokine 11 measurement · score 0.18
- apolipoprotein A 1 measurement · score 0.16
- fetal genotype effect measurement · score 0.14
- type 2 diabetes mellitus · score 0.13
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q13508-F1 | alphafold | PREDICTED | 74.01 | — |
Amino-acid sequence (389 residues)
MKTGHFEIVT MLLATMILVD IFQVKAEVLD MADNAFDDEY LKCTDRMEIK YVPQLLKEEK ASHQQLDTVW ENAKAKWAAR KTQIFLPMNF KDNHGIALMA YISEAQEQTP FYHLFSEAVK MAGQSREDYI YGFQFKAFHF YLTRALQLLR KPCEASSKTV VYRTSQGTSF TFGGLNQARF GHFTLAYSAK PQAANDQLTV LSIYTCLGVD IENFLDKESE RITLIPLNEV FQVSQEGAGN NLILQSINKT CSHYECAFLG GLKTENCIEN LEYFQPIYVY NPGEKNQKLE DHSEKNWKLE DHGEKNQKLE DHGVKILEPT QIPGMKIPEP FPLPEDKSQG NINNPTPGPV PVPGPKSHPS ASSGKLLLPQ FGMVIILISV SAINLFVAL
Explore Ecto-ADP-ribosyltransferase 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets